{"id":"W4408120470","doi":"10.3390/curroncol32030144","title":"Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Ipilimumab; Medicine; Nivolumab; Temozolomide; Melanoma; Internal medicine; Oncology; Dacarbazine; Cohort; Vemurafenib; Refractory (planetary science); Immunotherapy; Cancer; Chemotherapy; Metastatic melanoma; Cancer research","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002505319,0.0001570842,0.0002949144,0.000147383,0.0001367181,0.0002656372,0.0001184681,0.0001430423,0.0006074483],"category_scores_gemma":[0.0003382505,0.00007763792,0.0002704263,0.0001123157,0.0001225729,0.0001326578,0.0001749427,0.0004695354,0.0001232871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002253087,"about_ca_system_score_gemma":0.0001299059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004502396,"about_ca_topic_score_gemma":0.0007824092,"domain_scores_codex":[0.9998748,0.00002872072,0.000007106517,0.00003955465,0.0000215833,0.00002814649],"domain_scores_gemma":[0.9998214,0.00003463818,0.00005252412,0.00001512415,0.000009602334,0.00006663561],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03234445,0.001649549,0.4928574,0.0002103688,0.0004930999,0.002659091,0.0004962608,0.002267556,0.3316482,0.00009564626,0.001555444,0.1337228],"study_design_scores_gemma":[0.0002775784,0.01038444,0.9690606,0.00001063432,0.0001821157,0.002308964,0.0001384951,0.001328043,0.01475528,0.00006090027,0.001479772,0.00001320676],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994227,0.000174923,0.00008470509,0.00001979701,0.000003773,0.000007276297,0.00009357883,0.000006461849,0.0001867979],"genre_scores_gemma":[0.9995166,0.0000610734,0.00007281067,0.00002195395,0.000004151961,0.00000485388,0.000194823,0.000002153132,0.0001215279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0006074483,"threshold_uncertainty_score":0.002032161,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02762971656290505,"score_gpt":0.3734036846423527,"score_spread":0.3457739680794477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}